myALZteam

Donanemab (brand name Kisunla) is one of the newer FDA-approved treatments for early Alzheimer's disease. It works by targeting and clearing amyloid plaques that build up in the brain, which are believed to play a role in the disease's progression.

Here are some key things to know:

- It received full FDA approval in July Show Full Answer

Donanemab (brand name Kisunla) is one of the newer FDA-approved treatments for early Alzheimer's disease. It works by targeting and clearing amyloid plaques that build up in the brain, which are believed to play a role in the disease's progression.

Here are some key things to know:

- It received full FDA approval in July 2024
- It's given as an IV (intravenous) infusion
- Before starting, amyloid buildup must be confirmed — usually through a PET scan or spinal fluid test
- Long-term data suggests it may slow cognitive decline over 3+ years
- Early treatment appears to offer the most benefit Like all medications, there are some important risks to be aware of:

- Brain swelling or small bleeds (seen on MRI scans) — this affects roughly 35% of users, though a modified dosing schedule may reduce that risk by up to 41%
- Headache
- Increased risk of falls
- Allergic reactions

Regular brain monitoring is required while on this treatment. It's not a cure, and it does come with practical challenges like the cost and the need for IV infusions. That said, it represents real progress in actually targeting the underlying disease rather than just managing symptoms.

Talking with a healthcare provider is the best way to find out if it could be a good fit.

 AI-generated responses are not a substitute for medical advice. These services are not intended to diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.

Early-Stage Alzheimer’s Clinical Trials: What To Expect

6 Ways To Treat Alzheimer’s Disease